GETSET: Preimplantation Genetic Testing in Women of Advanced Maternal Age

Sponsor
Genomic Prediction Inc. (Industry)
Overall Status
Recruiting
CT.gov ID
NCT04167748
Collaborator
(none)
240
1
2
44.9
5.3

Study Details

Study Description

Brief Summary

The GETSET trial is a prospective randomized trial designed to evaluate the clinical outcomes of incorporating preimplantation genetic testing for aneuploidies (PGT-A) in elective single embryo transfer in women between 35 and 40 years of age.

Condition or Disease Intervention/Treatment Phase
  • Procedure: Preimplantation genetic testing for aneuploidy (PGT-A)
N/A

Detailed Description

In this randomized controlled trial, a total of 240 patients divided evenly across the two participating IVF centers will be recruited. Patients will be randomized to a control and to a treatment group, each containing 120 participants.

Only patients with at least one evaluable blastocyst will be randomized. Patients will undergo ovarian hyper-stimulation, oocyte retrieval, fertilization and embryo culture per standard clinical protocol determined by IVF center.

In the control arm, patients will undergo a single frozen embryo transfer with an untested blastocyst with the best morphology. All other blastocysts with lower morphology will undergo trophectoderm biopsy on day 5, 6 or 7 and will be frozen. PGT-A results of the untransferred embryos will be revealed to the patient AFTER the outcome of the initial ET is known. If the initial transfer results in a non-conception cycle and additional euploid embryos are available for transfer, these cycles will be followed and their outcomes collected.

In the experimental arm, all embryos will be cultured to blastocyst and all viable blastocysts will undergo trophectoderm biopsy and PGT-A. PGT-A will be performed regardless of the number of blastocysts available. Patients will undergo frozen transfer of the single, best quality euploid blastocyst. If the initial transfer results in a non-conception cycle and additional embryos are available for transfer, these cycles will be followed and their outcomes collected until the embryo cohort is exhausted.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
240 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Intervention Model Description:
Prospective randomized clinical trialProspective randomized clinical trial
Masking:
Triple (Participant, Investigator, Outcomes Assessor)
Masking Description:
Allocation information will be handled by researcher coordinators only.
Primary Purpose:
Treatment
Official Title:
GEnetic Testing in Elective Single Embryo Transfer in Women of Advanced Maternal Age
Actual Study Start Date :
Mar 5, 2021
Anticipated Primary Completion Date :
Nov 1, 2023
Anticipated Study Completion Date :
Dec 1, 2024

Arms and Interventions

Arm Intervention/Treatment
Experimental: PGT-A transfer

Transfer of single chromosomally normal (euploid) blastocyst after PGT-A

Procedure: Preimplantation genetic testing for aneuploidy (PGT-A)
24-chromosome screening for aneuploidy in the preimplantation embryo (blastocyst stage)
Other Names:
  • Preimplantation genetic screening (PGS)
  • No Intervention: Untested blastocyst transfer

    Transfer of single untested blastocyst based on embryo morphology criteria.

    Outcome Measures

    Primary Outcome Measures

    1. Ongoing pregnancy rate [Up to 18 months]

      Number of patients who experience an ongoing pregnancy rate (>20 weeks of gestation) after their first embryo transfer

    Secondary Outcome Measures

    1. Miscarriage rate [Up to 18 months]

      Number of patients who experience a miscarriage after their first embryo transfer

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    35 Years to 40 Years
    Sexes Eligible for Study:
    Female
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • Women undergoing IVF of between 35 and 40 years of age at IVF cycle start

    • Utilization of Intracytoplasmic Sperm Injection ICSI

    • Utilization of ejaculated or testicular sperm

    • Utilization of autologous or donor sperm

    • All Controlled Ovarian Hyperstimulation (COH) protocols

    Exclusion criteria:
    • Patients with anovulatory Polycystic ovarian syndrome (PCOS)

    • Utilization of donor oocytes

    • Utilization of gestational carrier

    • Recurrent Pregnancy Loss (RPL) defined as ≥ 3 consecutive miscarriages

    • Recurrent Implantation Failure (RIF) defined as ≥ 3 more failed embryo transfers

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 IVF Florida Reproductive Associates Margate Florida United States 33063

    Sponsors and Collaborators

    • Genomic Prediction Inc.

    Investigators

    • Principal Investigator: Nathan R Treff, PhD, Genomic Prediction

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    Responsible Party:
    Genomic Prediction Inc.
    ClinicalTrials.gov Identifier:
    NCT04167748
    Other Study ID Numbers:
    • Genomic Prediction Inc 624
    First Posted:
    Nov 19, 2019
    Last Update Posted:
    Mar 15, 2022
    Last Verified:
    Mar 1, 2022
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Mar 15, 2022